Article 02
Understanding your Heart Health with StoreGene
The Most Comprehensive Genetic Cardiovascular Analysis on the Market
Why does Genetic Testing for Heart Health Matter?
Heart disease is the leading cause of death worldwide, yet it’s also one of the most preventable through early detection and proactive adjustments (1)(2). Your genetics plays a significant role in your risk of heart disease. Understanding this can empower you to take control of lifestyle factors like diet, exercise, and stress management to decrease your risk.
At StoreGene, our genomic Heart Health pack is designed to provide you with a detailed understanding of your unique genetic makeup and how it impacts your risk of cardiovascular disease. A single test can identify multiple individual genetic markers linked to cardiovascular disease risk, offering you and your healthcare provider actionable, tailored insights. These genetic insights can help you and your clinician develop an informed and targeted healthcare plan, enabling more precise medication selection, lifestyle recommendations, and monitoring strategies.
Whether you have a family history of heart disease or simply want to take control of your future health, StoreGene’s heart health analysis equips you with the knowledge you need to manage or even reduce your risk of developing heart disease.
What Sets Our Heart Health Analysis Apart?
StoreGene’s heart health analysis goes far beyond traditional testing by only using whole genome data to provide a complete picture of your cardiovascular risk (find out why whole genome sequencing is essential here). From one single test, our advanced analysis delivers three distinct insights: monogenic reports for single-gene conditions, polygenic reports for multi-gene risk factors, and pharmacogenomic reports to guide medication choices.
Moreover, whole genome data means we can use the Meta- Genetic Risk Score (metaGRS) approach to provide far more detailed insights than traditional techniques by evaluating over 1.7 million genetic variants(2). This unparalleled level of detail and precision allows us to identify genetic risk factors for heart disease more accurately than any other tested genetic risk score, helping to uncover variants that might otherwise go undetected in traditional health screenings.
Additionally, we prioritise your privacy, ensuring that your genetic data is securely stored and only shared with you and any healthcare providers you choose. Read our privacy notice for more information.
What Does Our Heart Health Analysis Include?
- Genomic and Conventional Risk Assessment: Combines genetic risk information from 1.7 million variants with conventional risk factors like BMI, blood pressure and cholesterol levels to determine the 10-year likelihood of developing cardiovascular disease.
- Estimated Cholesterol and Lipid Concentrations: Certain genetic markers can impact your natural cholesterol and lipid levels. By understanding these markers, you can gain insights into how your body processes fats and identify whether you may be predisposed to high cholesterol, which is a major risk factor for heart disease.
- Familial Hypercholesterolemia: This test identifies known genes associated with this common genetic disorder, also known as FH. Having FH causes a build up of fat in your coronary arteries, blocking blood flow to your vital organs and increasing risk of heart attack, stroke and early death (3).
-
- It affects 1 in 250 people – around 270,000 in the UK – yet many are unaware they have it.
- If you have FH, there’s a 50% chance you could pass it onto your children.
- Medicine Management: Adverse drug reactions are estimated to be the 4th leading cause of death worldwide (4). StoreGene’s pharmacogenomics analysis identifies genetic markers that influence your response to medications like blood thinners or cholesterol-lowering drugs, enabling you and your doctor to make informed treatment decisions.
-
- For example, individuals with SLCO1B1 genetic variants may experience muscle pain (myalgia), muscle weakness (myopathy), or severe muscle breakdown (rhabdomyolysis) in response to heart medication, which can affect an estimated 11% of patients (5)(6).
What to Expect After Your Heart Health Analysis
Our testing process is easy to complete and can be done from the comfort of your home by ordering and completing a simple blood test and sending it back to us. Once we have received your blood sample, and testing and analysis is complete, final reports will be sent to your specified health care professional within 30 working days. If you do not have one, please refer to our Clinical Partners list.
This report is designed to be easy to understand, with clear explanations and actionable insights. Your designated clinician will be able to discuss the results and potential lifestyle changes, preventive steps, and, if necessary, medical interventions.
Get Started with StoreGene’s Heart Health Analysis
Take charge of your health today, reach out to an affiliate clinician, order your heart health package today, or contact us to speak to a member of our team to learn more about our product.
References
- Tada, Hayato et al. “Human genetics and its impact on cardiovascular disease.” Journal of Cardiology, vol. 79, no. 2, 2022, pp. 233-239, https://www.journal-of-cardiology.com/article/S0914-5087(21)00237-9/fulltext.
- Inouye, Michael et al. “Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults.” J Am Coll Cardiology, vol. 72, no. 16, 2018, pp. 1883–1893, https://pmc.ncbi.nlm.nih.gov/articles/PMC6176870/#abs0010
- British Heart Foundation. “Familial hypercholesterolaemia: symptoms, causes and treatments – BHF.” British Heart Foundation, 2024, https://www.bhf.org.uk/informationsupport/conditions/familial-hypercholesterolaemia. Accessed 23 December 2024. https://www.bhf.org.uk/informationsupport/conditions/familial-hypercholesterolaemia
- Chenchula, S et al. “A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.” Nature, The Pharmacogenomics Journal, vol. 24, no. 9, 2024, https://www.nature.com/articles/s41397-024-00326-1
- NHS England. “Results: Patient with known SLCO1B1 genotype requiring statin therapy.” NHS Pharmacogenomics, https://www.genomicseducation.hee.nhs.uk/genotes/in-the-clinic/results-patient-with-known-slco1b1-genotype-requiring-statin-therapy/#:~:text=Statin%20metabolism%20is%20mediated%20by,of%20statin%2Dassociated%20musculoskeletal%20systemsv
Pereira, NL, and RM Weinshilboum. “The Impact of Pharmacogenomics on the Management of Cardiac Disease.” Clin Pharmacol Ther., vol. 90, no. 4, 2014, pp. 493–495, https://pmc.ncbi.nlm.nih.gov/articles/PMC3912556/.